$80 Million

Biohaven Pharmaceutical

Private Placement

Lead Placement Agent, November 2016

Biohaven is a privately-held biopharmaceutical company with particular expertise in late stage clinical development with a portfolio of multiple late stage drug assets. Biohaven has licensed intellectual property from Yale University, Catalent, ALS Biopharma LLC, Massachusetts General Hospital and two undisclosed pharmaceutical companies. The company has advanced multiple candidates into the clinic and plans on pivotal trials beginning late 2016.